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Abstract
l’.Ja live H.awalians hv vs h/oh incidence ies cli concers daa.nmeH
ec.dre. attitudes, and .o,acncee. cli Ha wa. 0! cO/c tus Is vvitli r.egard
cancer trearmenr c/in/cal trials and Native Hawaiian participatbn id
them. Findinqs suggest that mnst cancer specialists are spopcrtive
of ciindai trials. However, physic ans ide.n ti/led a number .o.l barriers
10 SJaIue/ Ian s:ao oarrc.caccr .n cvn:a Ira:. limvs to .ricreasv
orsil.cQarc’ ymca nas a’s suooesed.
Introduction
Native Hawaiians have the second highest overall cancer incidence
rates and the highest ace-adjusted cancer mortality rates in Hawai’i.
When compared nationall\ Nativc Hass ailans have the fourth
highest incidence rates and the second highest mortality rates for all
cancers combined. Higher rates of cancer mortality can be attrib
uted, in part, to the fact that many Hawaiian cancer patients present
with late-stage cancer and have poor access to state-of-the-art early
detection and cancer care.
Advanccs in cancer treatment and pres ention can be achieved
through neon ms scientific testing. of new cancer rreai men t and
prevention strategies through randomi,ed clinical trials. Random
ized clinical trials are controlled experiments that randomly assign
patients to one of two or more treatment groups for the purpose of
evaluating the most beneficial treatments or cancer detection and
erition methods. Clinical trials offer patients access n state—of—
the-irt thcrap\ iii a reearc h cc mtext.
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A limiting factor in advancing cancer treatment and prevention
has been inadequate accrual ot patients onto clinical trials. Nation—
ally, fewer than 30 of cancer patients enter onto clinical truils. and
minority representation is much less: Locally, about 20 ol Hawaii
residents diagnosed ss tb cancer participate in clinical trials.”
Previous studies have identified barriers to clinical trials.
Borrowing from Gotav. \ve summarize three categories of variables
that affect accrual to cancer treatment clinical trials— -physician
factors, patient variables, and trial characteristics.
Phs sician Factors. Many phr sicians do not refer their patients to
clinical trials hecause they lack support staff and/or have concerns
about cc ordination of and compensation for care if a patient joins a
clinical trial. (.)thers may belies e that the answer to the research
question under studr is already known or mar has e a prel’erence for
a specific treatment option Still others may perceis e a conflict in
role clinician \ ersus researchert. be concerned that the doctor
patientrelationship will he affected, ordishike discussions involving
uncertainty, which could undermine a patient’s confidence in the
physic ian. Ph sicians mar not refer because they feel a trial is
inappropriate given a specitic patient’s phr sical. mental, and social
conditons. Ftnallv. ph sicians may be unass are of specifc trials
asailable to their patients - The most common physician factor
influencing cancer patient enrollment, however, “is that the patient’s
physician made a decision not to enter the patient in a trial.”
Patient Barriers. Ritients mar not s’, ant to enter clinical trials
because ther do not has e enough information about the trial and/or
do not base eunuch time to make a decision about participation.
Sonic patients do not ss am to be “guinea pig” in a test of an option
that might not work or mriay he more burdensome or cause more side
effects than standard treatment. Others distrust Western medicine.
Oihem may has e limited insurance or income and or he dissuaded by
Personal tactoms such a’ aoe co-niorhiditie” and family opinion.
Trial Factors Accrual is also dependent on the characteristics of
thy tnt il includiny to d is uI ihilits cli eihihts dcsign informcd
consent procedures, and mode oh presentnmion of in formation.
A studa of physician knowledge, attitudes, and practices melatinc
tO linicai tmeik us conducted t gain inicht into specific uccruul
issues in Hass ai’i. Our objeedves were to identify harriers to
physic.ian reforral of Native Hawaiian patie.nts to cancer cii.nical.
trial’ and to recommend imems emions to increase accrual and
rctcmitn ui,
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Methods
Sample and Survey i)istrihution
Following appros al of the \aii\ e Hawaiian Heahh Systems lnstiin
tional Re\ ca Board, a questionnaire was nailed to all X eaneer
spcciahv phr sicians prautienla it the state of Hawaii (ineludinc
medical one I gits. radiation therapists, and nraeons that perform
cancer-related ‘nraersi. a ith a stamped. cairn ens elope. F\vo
weeks later, an k’nticai qnc tinnaircaas mailed to non-respoit
dents and. beginning two a eeL. al/er that, thro e a more reminder
ph.one. calb.’ were made to the remain.i.ng non--respondents. Data
received h February 1, 200 1 were inc.iuded i.n t.he a.naiysis, Survey
e.nveiopm.: we-re c.oded so t.hat individual surveys we.re not linked
with names.
\leasures
.-\ t’eviea ot thc literature on patient accrual to elttiicai trials guided
the desien ci the 2a-i em. cr -‘ectional survey tool ne--pave and
double-sided Dentoaraphic item’ taped cthnmeitv. medical spe
cialtr, years in practice, training experience. urrent practice bc a
non and sire, and percentage of Hawaiian/Part Hawaiian patients in
the physic.ian’ s prac.tiee. A defini.ti.on. for caticer tre.atmerit clinical
trials was provided. a.nd five items queri.ed i.nterest i’r. t.riai.s. comfort
wtth discus sing trials, number of cancer patients seen each month
and, of these. the numherofcanccr patients engaged in a clinical trial
discmmmon and number Ol patients that actuallr entered a trial. The
nextqucstmona’kcd t’oracrcentent iornot a th I 7 lactors that miket
deterphosicion’ tromn discussirs a treatment trial withapatient cc..
trials are not in want to m\ ractice. titer’ tke pc much tune. etc.:
see ‘Fable 4 tori cmtmpietc istu Another series of items asked hoa
cc cl informed phr stcians felt about available trials and othercancer
telated servtees. if they would like more information and, ml so.
which sources would he most influential, Open-ended qrtcstlons
provided opporlunities for respondents to write more about harriers
and to suggest a ha few Native Hawaiians parttei pate in trials
,-naiysis
Responses a crc entered iwo [pt-Into .apmtblic-dontain provramtt
developed hr the Centers t a Disease Control and Pm’esenth mm -
\Icans and trcmucmtcmcs svcrc calculated.
Results
Respondent Characteristics
Compiete.d surveyr. were. returned by 47 (‘5320 of the car.cer spe
clait physicians, Approximately hal.f of the respondents were.
medical. oncole’ ists and:, one-third we-re.- cancer surceons: 81
attended a residenco or tdlloccship pmocram cc oh : trune cninliaos
on cunical triats [able I ‘. \pnri’xintatc[ halt acme Caucasian and
only c’necc-a- Native Hacv:m:iami Nl’5t 0’ . s’cem’i-praetcmmtv n
(t’,ihu Half 0 the ‘es ondent’ hod 2(1(1 to thIn isatmeimts in their
current. l.eaei:ce. and t.wo--thids 0’ rcsps. .nde fits estimated that
200/
. -f their patients were Native Hawaiian.
Participation in Cancer Treatment Clinical Trials
Approx.i.rnatelr, two-thi.rds 01 responde.nts sal. d the-y were “ver
in tereste.d” inca fleer treatment eh rt ical trials, and were “very c
fortuNe” diseussinu tt’ia Is with their patients- i10hle 21. N—lust
the rc’sponsh m1t 5uid that tires’ Ira di5crmscd linieal tt’ial -s dir
their patients in the past c-ear, and on as erage, these phr sici:ms had
disenssccl ‘lnieal trial’ a-nh about 4() patenls in the pa>t rear, Fut
ii phr ‘isians. boa cc ci’. none-cl the patients with o. hoimi rices-
discussed trials aetualls entered theni, The remaining 20 phr sicians
m’eported an average of patIent enterinc elmnical trial’ in the piw
s-ear, The number of patieitts with cc hun trmoils wem’e dieuseda’ud
the number of patiettts ettterimig trials dmt 1cm-ed by specialtr. highest
for nedieai oncologists attd lowe-st ‘for rad:ation oncolu ists. This
is not surprising, since most curre.nt clinical t.t’rals require radiatioi-r
oncologists- to refr-sr patients to medical oncologists lee study regis
tration, See. Table 2 om-m mmcx t page”I
Aw arcne%s and t,se of CancerReIated Ser ices
OuR- ,ihont halt’ i5,t belt “very cceil” imt(’smm’mmred amn’Lmt a
caneermms’:mtmentc’imnmcai trials, armd NV cc ct-c interested it
nt ‘rn(timlon cmi trials lahle S a \‘lore tl’tair halt
pm-eterresl eermic’ ti.i : nllrrmrr:lti.on ftcsm the- (‘am:teer Reseauch Cetttet
of .Haa ad I (CRCHi,
Respondents w-ere asked Of they were aware. of and had used three
cane-er-related programs s-ponsore.d and f/mnded by the N’ationa.l
Caric.er li-tstitute- (‘NCIi: the Cancer lit firmation Set-v ice (Cf-Si
Physician - s Data Quer— iPDQ/, and (“ate-er Re.searc- 0 C’enter of
H i rIft H I 20 II 0 N mci is t
Table 1 -— Sample characteristics (n=471
chineSe
F/gino
0/panes-c
Native Hr-wa/an
P4<0 Or other
0050<
How many patents are you stowonsibie
(or in -our ourrent p-raotice?
<200
200-- 500
51:0-1,000
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Table 2.— Interest, comfort. and participation in clinical
cancer treatment trials n=43i
What V vo•u< comfort level in disousrtno cancer treatment
clinical triais air your patients?
Very interes.ted
Somewhat interested
Not at at interested
Per pbs S eiapnsed anc se earn man
Suoeon
Per envsa tan tn$Ot, estimated rruniber caccer catients.
in past ear with whom o)nical trias wers. discussed
Medical oncologists (n=22)
Surgeons in..12)
Radiation 0000logists (n=Si
Overa) (n=40)
Per physioiarr in24), estimated number ot cancer patients
who entered c(nicai triais,
Medical oncologists (m16)
Surgeons w1O
Rad anon orco:og vs
Peverms nay sum to iess than ‘tn me to rrnssvrg oats
care providers. iher also offer cancer information including
information about clinical trials) to the general public. palicnts. and
famil members, Most (81 V) ol’ph sicians said they a crc aware of
CIS, and 60<3 had used it. The PDQ is a Weh4sased resource that
provides uptodate reviews of the scientific literature related to
cancer prevention, detection, treatment, supportive care and genet
ics. as well a inventories and contact information t3r clinical trials
and cancer organizations, In all. Xl oti’espondents said they were
aware of Pl)Q and 62<3 had used it. The CRCH. through its
Minoritr bascd (‘ommunit\ Clinical Oncolog Program. cnipluvs
support siff ri< amlahle to help phn sicians present information ahout
cancer clinical trials to patients and to assist with the informed
consent po ‘ccss. Among onr respondents. ‘0<3- were ass arc of this
rorani utsl hadaccessed it. Additionally. P4C siid thee sscre
oaarc of limiT suppoi’t groups or cancer patients and their families.
and 83< had referred patients to support groups.
Barriers to Discussing Clinical ‘Trials
Phy sicia.n.s we•re asked to atcree (or not) wit.h. state.me.nt.s re.Iate.cl. to
phyt.rician. patient. a.nd tria.i •factors th.at mih.t. de.ter th.em from
discussing trials with their patients (Table $ .An peioended
question all aced them to give reasons he Native Ham aian partieC
pation in trials mar he pamcul<irlr <‘a
Phsician_Factors, Ten pltr siciamorelated harriers were included
in the sun cv and agreement that these items a crc harriers a as
genei’allr low. In fact. onlr four ot the ten physican tactors were
seen as deterrents by 25’ or more of the rcspondine phssicmans. HI
these, three items had to do a th tune and cost i not having enouch
cuppflm’t slaP’ to manage trials. not feeling adequately compensated.
and feeling that it was too difficult and time consuming to provide
mnlormedconsent, The fmn’th physician factorconcernedphr sician
preference for one of the treatment arms of a study. Additionally,
I 9( felt that available clinical trials were not important to their
practice.
Patient__Facs. Of the f3ur patient factors, 2503 or more of
physicians agreed that three served as deterrents to trial accrual—
patient refusal, patient cry morhidities, and lack of transportation.
[ii ill at Moi c th in of rvspond nis s im ala of thc. thrm.
trial fdctors as detei’i’ent. Fhey felt clinical trials acre too timic
consuming. me rem 0 innosr<t\e. and did not address questions
ivIes amit to their patients
I atoi I) t,rmtn., \atm\ H iii in P utijJ_jp’n ha pm and
qriestion elicited a nunibcr f reasons for low clinical trial panticipa
tion b\ Natis c- 1 laaaiian5. Sc’sei’ttl retVrred to cultural tactors. eu..
that ati\ e l-lawaiians have <cultural bias against \\ estern medicine
nm5
. tear diagnosis and theraps n3 rt and pi’eftr to try Hawaiian
traditi’..’nal remedies or other aite.rnative. appi’oaehes.. (n=4), Two
physicians conunented. on the difficulty in r’etti.nu i nfbi’me.d. c.onse.nt.
and one of the.se physic.ians wrote, “It’ <•‘ hard for a ph.ysieian to ta.ik
story long enough for Nati v e Hawaiian patients to feel comfortable
iominrt a n’iai.” Re.Iat:ed to this were two comments on quality ofi.ifd.
A pli sician svrote that. to Native Hawaiians. “qua) ty of life is much
mime important than quanmitr ‘ Another noted that Natise Ham
Table 3.— Awareness and use of cancer-related
information sources and services in=47i
- .‘, .
- -,
Prom which sources?
Cancer Research Center
Turn or boards
Con.terences
Serve
PhvsVtans Data Query tPDQ
Support staff from CRCH
Cancer support groups52 rear
30. ‘ear
Ptyear
40/year
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inns were reluctant to join clinical trials because they had ‘‘witnessed
sutiering and lack ot improvement from chemotherap in their
families.”
The second category encompassed access issues, including socio
economic barriers n=4 and lack of Native Ha aiian physicians.
especially in cancer specialties n=l A third categor concerned
edLication, cc., Native Hawaiians lacked infornmtion about cancer
and screening recommendations (n=3) and that they had a poor
understanding of the process and benefits of clinical trials (n=5.
A phsician commented that, “Most people. including Nati e
Hawaiians. would rather go ssiih pros en results.” sshile another
cited “guinea pig’’ mentality. Two noted that Native Hass aiian
patients often presented with a number of co—morbidities that made
them ineligible for trials Another physician wrote that. “Clinical
trials ma not he ihe best prescription tbr the patient”
The final category encompassed pbs siciau is’,ues, e.g., clinical
trials are not offered by doctors ( n=5 . physicians are not interested
in clinical trials u= I ), and clinical research is not supported h the
medical community (n=l .
Discussion
Our hndings suggc’t that most cancer spec ialt\ physicians ted
comfortable discussing clinical trials with patients and are aware of
the services provided through NCI and CRCH. However. generali
muons iruist he tempered since not all phr sicians returned surver
and we do nut knuss the kunwlcde. attitudes, and practices ut nun-
respondents. Hosvcs er. —ince statistics show [bitt participation in
clinical trials is low, it appears that clinical trial participation rates
can he improved.
Barriers to clinical trial accrual identil ed by Hawai ‘i physicians
sseresinilartothusereported iii the literature. Additionally. Hassai’i
dues nut havc an intccrated staless ide s stein tur i mplcmcutino
clinical trials, most cancer specialists practice on O’ahu reducing
oppm’tunities for participation by neighbor islanders, and phvsi—
cians on O’ahu practice at a variety of hospitals with varying lex els
of support for clinical trials activities.
Programs to decrease barriers to clinical trial participation should
be implemented. ‘I he Governor’s Blue Ribbon Panel on Cancer
Care in Hawai ‘i. ss hic h issued a report in Au) I. made ts o sugges
tions that likel would help increase accrual to clinical trials,
• l—lasvai ‘i should establish an Outpatient Cancer Center, located
near mator hospitals. that would support the development ol’ a
comprehensive clinical treatment program in the state. This
center would oiler care coordination, health education, expedited
assessments (e.g., lab and imaging services), and multi-disciplin—
arv treatment planning. as well as clinical trial support. This one—
stop—shop approach would increase the efficiency and compre
hensiveness of cancer care, and save patients l’roin has ing to make
and keep multiple appointments in several diftdrent facilities.
• A statewide clinical trials system should he developed, supported
by this Outpatient Cancer Center and CRC’H. With this. Hass ai ‘i
could apply to beeome an NCI—designated Comprehensis e Can
cer Center, which would result in an increased as ailabil its’ of’ new
treatments and clinical trials A coordinated, statewide system for
accrual to clinical trials should offer support staff available at
times and louations convenient to patients, address physician
compensation concerns, and provide opportunities for public
recognition at conferences and profess ioual dinners.
Other strategies may be ti’uitful as well. The literature describes
ideas for increasing accrual of minority Americans to clinical trials,
sevei’al of ss hich ma svork in l-lawai ‘I.
* Native Hasvaiian health care providers could be enlisted to help
recruit Native Hawaiian participants to clinical trials. (Jufortu—
natelv. at the pi’esent time, only 4ff of Hussai ‘i ph\ sicians ate
Native Hawaiian and univ one oncologist is Native Ilasvaiian
Else ci al, y)(37 l’he oncology nurses socieE includes Natisc
l-law’aiian nurses who may also agree to assist in recruitment.
Scholarship programs. established to increase the number of
Natis e I law anans in the health pt’ufessions, are helping to correct
this disparity.
• Educational programs for clinical trials should provide culturally
appropriate informational materials in Ian’ language and should be
distributed at professiunal. church, and cummunitv uk’etings and
at health fairs and sportine events. Public sers ice annt uncemcntc
Iiould he pros ided tu Hawaiian music radio stations. newspapers.
and newsletters of Native Hays aiian organizations.
• \lan individuals are uit]uences by personal testtmonials, and
peer counseling has been effective in some minority cominnni -
ties. Such a pronrain in Hassai’i could link trial-eligible mdiv i5lu
als with current and former participants in clinical trials.
Although iUOt cancer patients in Flasvai’i do 1101 participate in
clinical trials, this tudr shorved that l-lawai’i onculocists liavv’
positive attitudes dout the value of clinical trials for their patients.
Table 4.— Barriers to discussing clinical cancer
treatment trials with patients (n47)
Physician factors
Nol n.a’.’e encuat succor: mart
Preference for one of the treatment arms in the sludy
Providing informed consent too difficult, time consuming
Not adequately compensatec.
Irma no: noolan! mu o’acrce.
Not cm’fo’:aoe suoeffrc oahenr.s to
Expiainmg treatment arms undermines patients conhdenci’n me.
Trials interfere with the doctor/patient reiationship.
Concerned my patient may transfer to another doctor,
Patient factors
Patients ‘euse to narlicioate. 23 42
Patents “ave cc-rro’bioaes. ‘8 38
Patents lack transportation. 12 2S
Patients thck insurance. 8 )f 7)
Trial factors
Cnn.cai tr.als are too time ccnsumn’c. 1532
C/rica trials not “novaf:ve.
T5as do not acdress questons ‘eeuan: :o mu palerns ‘2 26
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. ha c sumc, i no r h of s th’it th process of clinical
ttial, acctu il t mht h cnhlnc.Ld Th implementation of ‘,uch
chat s coupled ith 0 itinr in’s phvsi iin support his the pot n
ti Ito e\pand din 11 i I particip itton to local cancer patients
\ iti Has tii is n p ritculat
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Free Hotline 24 Hours a Day.
POISON CENTER TIPS
• Keep the number 0f the Hawaii Poison Center on
or near your telephone.
• if you suspect a poisoning, do not wait for signs
and symptoms to develop. Call the Hawaii Poison
Center immediately.
• Always keep Ipecac Syrup in your home. (This is
used to make a person vomit in certain types 0f
poisoning.) Do r use Ipecac Syrup
unless advised by the Hawaii Poison
Center.
• Store all medicines, chemicals, and household
products out of reach and out of sight, preferably
locked up.
• A good rule to teach children is to “always ask
first” before eating or drinking anything—don’t
touch, don’t smell, don’t taste.
Donate to help us save lives.
Mail checks, payable to:
Hawaii Poison Center
1319 Punahou Street. Honolulu, HI 96826
OAHU: 941-4411
NEIGHBOR ISLANDS TOLL-FREE:
95
